Standard BioTools (LAB) Competitors $1.38 +0.01 (+0.73%) Closing price 04:00 PM EasternExtended Trading$1.38 0.00 (0.00%) As of 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LAB vs. TXG, EYPT, ALNT, AEHR, TRNS, CTKB, SENS, FEIM, QSI, and QTRXShould you be buying Standard BioTools stock or one of its competitors? The main competitors of Standard BioTools include 10x Genomics (TXG), Eyepoint Pharmaceuticals (EYPT), Allient (ALNT), Aehr Test Systems (AEHR), Transcat (TRNS), Cytek Biosciences (CTKB), Senseonics (SENS), Frequency Electronics (FEIM), Quantum-Si (QSI), and Quanterix (QTRX). These companies are all part of the "measuring and control equipment" industry. Standard BioTools vs. Its Competitors 10x Genomics Eyepoint Pharmaceuticals Allient Aehr Test Systems Transcat Cytek Biosciences Senseonics Frequency Electronics Quantum-Si Quanterix Standard BioTools (NASDAQ:LAB) and 10x Genomics (NASDAQ:TXG) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation. Which has more risk & volatility, LAB or TXG? Standard BioTools has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2, meaning that its share price is 100% more volatile than the S&P 500. Do insiders & institutionals have more ownership in LAB or TXG? 53.7% of Standard BioTools shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 23.2% of Standard BioTools shares are owned by insiders. Comparatively, 10.0% of 10x Genomics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate LAB or TXG? Standard BioTools presently has a consensus price target of $1.55, indicating a potential upside of 12.32%. 10x Genomics has a consensus price target of $13.65, indicating a potential upside of 3.99%. Given Standard BioTools' higher possible upside, analysts clearly believe Standard BioTools is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Standard BioTools 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.0010x Genomics 1 Sell rating(s) 8 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media favor LAB or TXG? In the previous week, 10x Genomics had 20 more articles in the media than Standard BioTools. MarketBeat recorded 24 mentions for 10x Genomics and 4 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.89 beat 10x Genomics' score of 0.77 indicating that Standard BioTools is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Standard BioTools 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive 10x Genomics 9 Very Positive mention(s) 0 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is LAB or TXG more profitable? 10x Genomics has a net margin of -13.13% compared to Standard BioTools' net margin of -69.08%. 10x Genomics' return on equity of -12.88% beat Standard BioTools' return on equity.Company Net Margins Return on Equity Return on Assets Standard BioTools-69.08% -20.23% -15.32% 10x Genomics -13.13%-12.88%-10.03% Which has preferable earnings and valuation, LAB or TXG? Standard BioTools has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStandard BioTools$174.43M3.02-$138.88M-$0.32-4.3110x Genomics$610.78M2.68-$182.63M-$0.70-18.76 Summary10x Genomics beats Standard BioTools on 9 of the 16 factors compared between the two stocks. Get Standard BioTools News Delivered to You Automatically Sign up to receive the latest news and ratings for LAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LAB vs. The Competition Export to ExcelMetricStandard BioToolsMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$527.15M$2.10B$5.70B$10.27BDividend YieldN/AN/A5.72%4.60%P/E Ratio-4.3134.9275.8626.51Price / Sales3.0210.06491.12165.50Price / CashN/A58.5825.8129.89Price / Book1.0911.6912.846.32Net Income-$138.88M-$63.67M$3.28B$270.51M7 Day Performance7.81%-2.07%0.22%2.15%1 Month Performance12.20%1.93%4.61%6.35%1 Year Performance-33.97%35.18%68.33%25.49% Standard BioTools Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LABStandard BioTools2.8607 of 5 stars$1.38+0.7%$1.55+12.3%-33.5%$527.15M$174.43M-4.31620Positive NewsTXG10x Genomics3.5566 of 5 stars$13.93-0.2%$13.54-2.8%-40.3%$1.74B$610.78M-19.901,240Analyst DowngradeEYPTEyepoint Pharmaceuticals1.8269 of 5 stars$13.65-2.6%$26.86+96.8%+47.4%$965.67M$51.90M-5.09120Positive NewsALNTAllient2.7827 of 5 stars$45.76+0.5%$35.00-23.5%+128.2%$771.77M$529.97M53.212,525Positive NewsAEHRAehr Test Systems2.2968 of 5 stars$25.19-1.4%N/A+122.4%$764.63M$58.97M-193.7590Positive NewsTRNSTranscat3.7824 of 5 stars$79.71+2.0%$112.20+40.8%-40.7%$728.57M$278.42M55.741,245Positive NewsShort Interest ↑CTKBCytek Biosciences2.0383 of 5 stars$4.10+2.0%$5.60+36.6%-19.3%$511.44M$200.45M-82.00500Positive NewsSENSSenseonics1.9244 of 5 stars$0.44-3.0%$1.54+246.6%+11.1%$361.39M$25.47M-3.4190FEIMFrequency Electronics1.4853 of 5 stars$32.64+3.3%N/A+121.2%$308.08M$69.81M13.21200News CoverageEarnings ReportAnalyst UpgradeQSIQuantum-Si2.3765 of 5 stars$1.06-1.9%$3.48+227.8%+36.5%$218.70M$3.06M-1.56150News CoveragePositive NewsQTRXQuanterix1.7742 of 5 stars$4.52-0.7%$11.75+160.0%-61.2%$211.42M$137.42M-2.48460Positive News Related Companies and Tools Related Companies 10x Genomics Alternatives Eyepoint Pharmaceuticals Alternatives Allient Alternatives Aehr Test Systems Alternatives Transcat Alternatives Cytek Biosciences Alternatives Senseonics Alternatives Frequency Electronics Alternatives Quantum-Si Alternatives Quanterix Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LAB) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Standard BioTools Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Standard BioTools With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LAB Stock Alerts